Lilly agrees to $690M drug settlement

Eli Lilly has agreed to pay $690 million to resolve some 8,000 claims that its antipsychotic Zyprexa triggered diabetes-related health problems. The drug company did not admit any wrongdoing in the settlement, which comes just months before the first of scores of lawsuits were scheduled for trial. The settlement would resolve about 75 percent of the cases faced by Lilly. Most of the claims revolve around accusations that prior to September 2003 the company didn't adequately warn patients about possible side effects of the drug, which was used to treat schizophrenia.

- read this story from the Indianapolis Star

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.